'Renal toxicity' diaporamas de présentation

Antineoplastics and Antianemics

Antineoplastics and Antianemics. Pharmacology I NURS 1950. Objective 1: Describe the general factors utilized to select the therapy used to treat cancer. Objective 2: Describe the general uses of chemotherapy in the treatment of cancer.

749 views • 74 slides

Antifungals

Antifungals. When to think fungus?. Diabetes Immunosuppresed Acidosis Neutropenic Already on broad spectrum antibiotics. Travel to location with an endemic fungal pathogen. Disturbances in the GI mucosa either by inflammation or mechanical. Burns Trauma Neonatal.

1.08k views • 63 slides

Chemotherapy and Biotherapy Agents

Chemotherapy and Biotherapy Agents. Objectives. At the completion of this session the participant will be able to: Identify common side effects for individual medications Describe nursing interventions for chemotherapy and biotherapy medications

816 views • 54 slides

CORE Case 4 Workshop

Petra Lewis MD Professor of Radiology and OBGYN Geisel School of Medicine at Dartmouth. CORE Case 4 Workshop. Learning objectives. Be able to identify some of the most common radigraphic findings in emphysema and COPD

569 views • 48 slides

730 views • 47 slides

Peptide Receptor Radionuclide Therapy PRRT

Peptide Receptor Radionuclide Therapy PRRT. Sofia N. Chatziioannou , MD Associate Professor of Nuclear Medicine University of Athens, School of Medicine Director of PET/CT, BRFAA. Lu-177 imaging. 18m follow-up. 177 LUTETIUM. Imaging ??? s. Well differentiated NETs

1.83k views • 47 slides

Peptide Receptor Radionuclide Therapy PRRT

Peptide Receptor Radionuclide Therapy PRRT. Sofia N. Chatziioannou , MD Associate Professor of Nuclear Medicine University of Athens, School of Medicine Director of PET/CT, BRFAA. Lu-177 imaging. 18m follow-up. 177 LUTETIUM. Imaging ??? s. Well differentiated NETs

475 views • 47 slides

Studies on Amphotericin B

Studies on Amphotericin B. Current Formulations and problems and where we fit in!. Scott C. Hartsel Chemistry Department University of Wisconsin-Eau Claire. Overview. An ominous threat What is Amphotericin B? The problem with Amphotericin B What are liposomes and what good are they?

1.05k views • 32 slides

ARV related toxicities Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

ARV related toxicities Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Dr Paula Munderi WHO Training Course for Introducing Pharmacovigilance of HIV Medicines 23 - 28 November 2009, Dar Es Salaam. Acknowledgements sources of slide material. Published data Jens Lundgren

461 views • 28 slides

NSAIDs and COX-2-Selective Inhibitors

NSAIDs and COX-2-Selective Inhibitors. R3 ???. History and Background. NSAIDs Most often used nonopiod analgesics 70 million prescriptions were given in 1991 $2.2 billion cost, worldwide over $6 billion per year First extracted from the bark of the willow tree(salix alba)

461 views • 27 slides

Bleomycin

Bleomycin. Catalina Cuervo. Outline of Topics. Introduction to Bleomycin Structure Mechanism Resistance Analogs Conclusion. Bleomycin. Phleomycin was discovered in 1956 by Hamao Umezawa

240 views • 23 slides

Antimicrobial Agents (General Considerations)

Antimicrobial Agents (General Considerations). Prof. R. K. Dixit Pharmacology and Therapeutics K.G.M.U. Lucknow dixitkumarrakesh@gmail.com. Objectives. After this lecture you will be able to answer General adverse effects of antimicrobials

652 views • 22 slides

At what stenosis percentage does renal occlusive disease cause hypertension? 20% 40% 60% 80%

At what stenosis percentage does renal occlusive disease cause hypertension? 20% 40% 60% 80% 60% (HTN from increased rennin release). What is the leading cause of renovascular hypertension? Fibromuscular dysplasia Radiation vasculitis Thromboembolism Atherosclerosis

271 views • 16 slides

Adverse effect of drugs

773 views • 15 slides

46 th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27 - 30, 2006

Effects of Tenofovir on the In Vitro Toxicity of Selected Antiretrovirals In Human Renal Proximal Tubule Cells. F Vidal, 1 JC Domingo, 2 J Guallar, 2 M Saumoy, 1 B Cordobilla, 2 M Giralt, 2 F Torres, 3 F Villarroya, 2 T Cihlar, 4 and P Domingo 3,5.

111 views • 11 slides

Presented by Frank Sistare, Ph.D. at the Nonclinical Studies Subcommittee of the

Presented by Frank Sistare, Ph.D. at the Nonclinical Studies Subcommittee of the Advisory Committee for Pharmaceutical Science March 9, 2000. Accessible Toxicity Biomarker Morning Presentations.

198 views • 10 slides